Introduction
Since 1948 streptomycin has been the antibiotic of choice for the treatment of pneumonic and bubonic plague. The recommended regime is 30 mg/kg body weight given intramuscularly in two divided doses per day over 10 days (Butler, 1983) . The treatment may be complemented with tetracycline, especially if patients are at particular risk from the toxic effects of a long course of streptomycin (McCrumb et ah, 1953) . The severity of plague, however, outweighs the risks of the side-effects of the antibiotic. In addition to its toxicity, the major disadvantage of streptomycin is that it can only be administered intramuscularly.
Effective alternatives include tetracycline given orally at a dose of 2-4 g per day divided into four doses for 10 days or chloramphenicol, administered intravenously with an initial loading dose of 25 mg/kg followed by a 10 day course of 4 g per day in four 1 g doses. The latter regime is recommended for plague meningitis (Butler, 1979) .
Antibiotics should be given prophylactically to household contacts of patients and others who may have been in close contact with a patient (i.e. hunting partners, work colleagues, attending medical staff if isolation facilities are unavailable). A 7 day course of oral tetracycline, 15 mg/kg per day, or an orally administered sulphonamide, 40 mg/kg per day are the regimes advocated for this purpose (Lambert & O'Grady, 1992) .
The relatively low incidence of plague, particularly in the developed world, and the absence of any streptomycin resistance strains of clinical importance has led to a complacent view of the therapy and prophylaxis of plague, hence the lack of change since 1948. Plague, however, can suddenly appear, often with devastating consequences. Furthermore, the widespread misuse of antibiotics, particularly in endemic regions such as South-east Asia, suggests that resistance will eventually emerge. Butler et al. (1976) compared the efficacy of trimethoprim-sulphamethoxazole with streptomycin in treating plague patients, and found that although all the patients survived, long duration of fever and occurrence of complications were less frequent in patients receiving streptomycin. The efficacy of a wider range of antibiotics including the "newer" antibiotics such as fluoroquinolones and third generation cephalosporins in preventing and treating plague infection in animal models has also been investigated (Shcherbanyuk et al,, 1992; Bonacorsi et al., 1994) .
In the present study the efficacies of doxycycline and ciprofloxacin were evaluated. Doxycycline is regarded as the least toxic of the tetracyclines with a long serum half-life (~ 18 h) which reduces the frequency of administration (Lambert & O'Grady, 1992) . It has been widely used and is well characterised with regard to long periods of administration, as a prophylactic antibiotic and for treating atypical pneumonias. Ciprofloxacin is a potent fluoroquinolone which is increasingly being used in clinical practice. It has proven effective against other Yersinia species (Hoogkamp- Korstanje, 1987 ) and like doxycycline is generally administered once or twice-daily. As both antibiotics can be taken orally, they are suitable candidates for prophylactic use as well as therapeutic use.
Materials and methods
Bacterial strain, storage and culture Y. pestis strain GB was used as the challenge strain. The virulence of the strain was confirmed in vitro by determining growth characteristics and detecting virulence markers by the polymerase chain reaction (PCR), and in vivo by animal passage. The bacteria were stored at -80°C on a "Protect" bead storage system described previously (Russell et al., 1995) .
All challenge cultures were grown in Blood-agar base (BAB) broth, and counts and organ isolates grown on Congo red or BAB-haemin agar as previously described (Russell et al., 1995) .
Antibiotic preparation
Solutions of doxycycline (Sigma) were prepared by dissolving the powder in phosphate buffered saline. Ciprofloxacin solutions were prepared by dissolving Ciproxin (Bayer) tablets in sterile de-ionised water and then filtering the solution. The concentration of ciprofloxacin in this solution was measured using a disc diffusion assay. 40 /il aliquots of a series of dilutions of the ciprofloxacin solution were placed in wells cut from Iso-sensitest agar covered with lawn cultures of Bacillus subtHis var. niger. The plates were incubated for 24 h at 37°C and the zones of inhibition of growth were measured and compared to zones of inhibitions measured from a dilution series of a solution of pure ciprofloxacin powder kindly supplied by Bayer, UK. The similarity in the diameter of the inhibition zones confirmed that the available ciprofloxacin from the tablets was as expected. 
Animal strain
Porton outbred mice, obtained in-house, were maintained in cages within a rigid wall isolator. They were subjected to a 12 h light-dark cycle and were allowed to feed and drink ad libitum. Previous studies (Russell et ah, 1995) have shown that this strain of mice is susceptible to Y. pestis infection, and the median lethal dose (MLD) of Y. pestis given intra-peritoneally was 23 cfu as calculated by the method of Reed & Muench (1938) .
Antibiotic administration
Eight groups of mice each containing 25-35 mice, were kept in cages of five. Antibiotics were given sub-cutaneously in 0.1 mL aliquots twice daily according to the regimes described in Tables I and II.   Table II 
Animal challenge
Twenty-four hours prior to challenge, BAB broth was inoculated with three or four beads charged with Y. pestis from the "Protect" vials and incubated overnight at 28°C. Six to seven hours prior to challenge, 9 mL of fresh broth was inoculated with 1 mL of overnight culture and incubated at 28°C. This subculture was serially diluted and 0.25 mL aliquots of the higher dilutions plated out on to Congo Red or BAB-Haemin agar for colony counting.
The animals were challenged with 0.1 mL of the serial dilutions of the subculture by the intra-peritoneal route. Each sub-group of five mice in each group received a different dilution of the subculture. The mice were observed for 20 days after challenge (14 days after the last antibiotic administration). Mortality due to Y. pestis was confirmed by organ and blood smears on Congo red agar, and organs were also smeared from survivors to assess whether or not clearance of the bacteria from the animal had been achieved.
The MLD was measured and the degree of protection calculated by comparing the ratio of the MLD following prophylaxis/treatment to the MLD without prophylaxis/treatment.
In addition to the groups described above, two groups of five animals not given either antibiotic, were challenged to ensure that the Y. pestis had retained its virulence, and two unchallenged groups of five mice received either 40 mg/kg ciprofloxacin or 40mg/kg doxycycline twice daily for 7 days to determine any toxic effects from the antibiotics.
Results
The groups of mice given ciprofloxacin prophylactically or therapeutically were exposed to log dilutions of Y. pestis ranging from 5.24 x 10 7 to 5.24 x 10' cfu ( Table I) . The doxycycline treated groups of mice were exposed to a range of log dilutions from 6.76 x 10* to 6.76 x lO^fu (Table II) .
Ciprofloxacin prophylaxis (both doses) afforded complete protection to the mice up to the maximum challenge. Therapy was less successful, although the MLD in the mice was increased to 2.0 x 10 5 cfu (8826 x MLD of untreated mice) and 2.2 x lO'cfu (9565 x MLD of untreated mice) for 40 and 20 mg/kg respectively.
The mean times to death of the fatalities in groups of mice given ciprofloxacin post-exposure were 51.0 ± 8.21 h for those receiving 40 mg/kg and 54.0 ± 7.77 h for those receiving 20 mg/kg. All deaths in both groups occurred either prior to the start of therapy or during the time that ciprofloxacin was administered.
Prophylactic use of doxycycline at 40 mg/kg increased the MLD to 1.6 x lO'cfu (686 x MLD of untreated mice). The prophylactic use of doxycycline at 20 mg/kg and the two therapeutic regimes were ineffective at challenges greater than 6.76 x lO^cfu (29.4 x MLD of untreated mice).
The mean time to death of the fatalities in the 40 mg/kg doxycycline prophylaxis group was 171.8 ± 22.42 h, with 78.6% of the deaths occurring after the antibiotic was withdrawn. In the other groups, mean times to death were 74.2 ± 10.39, 62.9 ± 11.10 and 49.6 ± 4.87 h for 20 mg/kg prophylaxis, 40 mg/kg therapy and 20 mg/kg therapy respectively. In each group the majority of deaths occurred during the administration period (83.3%, 91.3% and 96% respectively). The mean times to death of untreated mice challenged with 5.24 x 10 3 and 524 cfu were 80.8 ± 17.35 and 72.2 ± 9.11 h respectively.
The organs and blood removed from survivors at autopsy were all sterile, irrespective of antibiotic and dose regime. Generally, spleens were enlarged, and occasionally, there was hepatomegaly. These changes occurred in mice treated with both antibiotics and were not related to the size of the challenge or the antibiotic dose. Discussion Intra-peritoneal injection of virulent Y. pestis results in a widely disseminated, and rapidly fatal infection in mice. Although not a "natural" route of infection, this model probably represents a most severe infection, implying that success with an antibiotic under these experimental conditions could indicate potential success in the clinical environment.
Ciprofloxacin proved to be effective when used prophylactically. The absence of relapse following antibiotic withdrawal and the sterility of organs and blood of survivors showed that ciprofloxacin can clear the host of Y. pestis.
The lower success rate of therapy indicated that 24 h was too long a delay in initiating treatment, and the first doses of ciprofloxacin were ineffective in halting the established infection in the mice given a high challenge of Y. pestis. This is certainly true in clinical practice where delays in differential diagnosis of septicaemic plague (thus delays in initiating treatment regimes) are cited as the cause for the high mortality of this form of the disease (Butler, 1995) . Generally, however, the longer incubation period of the various manifestations of plague in man (2-5 days) would mean a longer period for the establishment of generalised infection, and more time to initiate therapy (with or without positive diagnosis). Doxycycline may have been ineffective for two reasons. First, the dose regime used may have been too low. The regime was designed to achieve identical tissue and blood levels to those achieved in humans. Originally, 40 mg/kg given three times daily was proposed. In a previous experiment, five Balb/C mice were given this regime 48 h prior to challenge, and maintained on it for 4^ days after challenge. Four out of five mice survived a challenge of 5.78 x 10 5 cfu (56116 xMLD), but the mice showed neurological disturbances which suggested doxycycline toxicity. Second, doxycycline has bacteriostatic activity, and affects only actively dividing bacteria. In the 20 mg/kg prophylaxis group, the dose may have been insufficient to prevent multiplication of Y. pestis. In the therapy groups, the bacteria may have reached sufficient local concentrations that by the time the doxycycline was administered, it was ineffective. In the 40 mg/kg prophylaxis group, there was some success in treating the infection as the MLD was increased and the mean time to death was extended. There was, however, a high relapse rate. The antibiotic was probably successful in preventing multiplication, but not in killing, the bacteria. The immune system, which would usually kill bacteria held in check by a bacteriostatic antibiotic, was ineffective as Y. pestis can express a variety of potent virulence factors which enable it to evade the immune cells. As soon as the antibiotic was withdrawn, the Y. pestis could multiply and kill the host. Subsequent experiments, extending the doxycycline dosing to 7 days post-challenge did not reduce mortality. The rate of relapse fell because more mice died during the antibiotic administration period.
Ciprofloxacin has been shown to be effective against a severe experimental Y. pestis infection of mice when used prophylactically, and with some success, when used as a therapy. It therefore may be a useful antibiotic to consider when treating plague. Doxycycline, however, was of little use against this type of infection. The nature of the experimental infection used in this work does not necessarily exclude the clinical use of doxycycline against plague, but may indicate that the effectiveness of the antibiotic may be limited for some forms of the disease.
